In addition to consolidating its business in developing countries, Unichem is working towards creating a global footprint by entering mature markets like North America and Europe.
To this end, Unichem has made significant investments in infrastructure to support international business. As a result, the company has made more than 500 product registrations across the world and more than 500 regulatory filings such as DMFs, EDMFs etc. It has filed 13 US ANDAs of which 7 have been approved with many more still in the pipeline.
By leveraging its competencies in R&D, manufacturing and business development, Unichem seeks to take advantage of attractive opportunities in the generic segment in developed markets.
Unichem's international operations are divided into three distinct regions:
Unichem's growing presence in the EU is driven through its 100% subsidiary, Niche Generics, UK.
Niche specializes in the development, licensing and marketing of generics in the European Union.
Niche markets its products through its own livery in UK and Ireland and through marketing and licensing agreements in other European countries like Germany, France, Denmark and Sweden.
Unichem has also collaborated with other European partners for product development and co-marketing agreements.
Unichem's foray into the Americas encompasses the US, Canada and Latin American markets.
As a cornerstone of its strategy for developed countries, Unichem has made significant progress in the US by launching own label products through its wholly-owned subsidiary, Unichem Pharmaceuticals (USA), Inc. Unichem is aspiring to become a major player in the US market by offering high quality and cost-effective generic APIs and finished products. Most of the company’s Abbreviated New Drug Application (ANDA) products are vertically integrated.
Unichem’s Chemical R&D and Finished Products Development teams in Mumbai and Goa (India) are actively developing APIs and finished products for launch in the US market. The company is also filing Drug Master Files (DMFs) and ANDAs to the US FDA on a continuous basis to support Unichem’s ambitious growth plans.
Unichem has joined hands with leading Canadian generic companies for product development and supply agreements.
Unichem's subsidiary company Unichem Farmaceutica do Brasil Ltda., will focus on the growing demand for generic products in the Brazilian pharmaceutical market. With its own infrastructure, Unichem is set to aggressively develop its business in Brazil.
In the Central American region, the focus will be on marketing Unichem's branded generics. Unichem has formed distribution and marketing alliances with the key players in many markets to make this possible.
Zone I comprises the rest of the world excluding EU and the Americas. Unichem's strategy in Zone I is to focus on high value-added branded generics by leveraging its core competencies.
Unichem has full-fledged representative offices in Kiev and Moscow and a liaison office in Ghana.
A subsidiary company in South Africa – Unichem SA (Pty) Ltd. – has been created to tap the South Africa market.
Besides this, Unichem has a network of distribution and marketing alliances in the Southeast Asian region, CIS, Eastern Europe, Middle East, Africa and in the SAARC countries.
To drive growth in these markets, Unichem works with its own Sales and Marketing infrastructure and distribution alliances.